Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery
Authors:
- 1 September 2019
- Vol. 166 (3) , 277-285
Abstract
No abstract availableKeywords
Funding Information
- Medical College of Wisconsin
- Medical College of Wisconsin
- Medical College of Wisconsin
This publication has 41 references indexed in Scilit:
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic CancerJAMA Surgery, 2016
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)Surgery, 2014
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial DesignAnnals of Surgical Oncology, 2013
- EMT and Dissemination Precede Pancreatic Tumor FormationCell, 2012
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: Rationale and Overview of the ConferenceAnnals of Surgical Oncology, 2009
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 2006